Thomas Steyer Farallon Capital Management
Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boston Scientific
BSX
|
+$166M |
| 2 |
Roivant Sciences
ROIV
|
+$137M |
| 3 |
Immunovant
IMVT
|
+$130M |
| 4 |
BridgeBio Pharma
BBIO
|
+$96.5M |
| 5 |
Baidu
BIDU
|
+$94.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$498M |
| 2 |
Amazon
AMZN
|
+$398M |
| 3 |
Charles Schwab
SCHW
|
+$372M |
| 4 |
Aon
AON
|
+$365M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$286M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 54.84% |
| 2 | Miscellaneous | 21.83% |
| 3 | Communication Services | 8.41% |
| 4 | Technology | 5.7% |
| 5 | Financials | 3.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
151
Novavax
NVAX
$1.64B
| – | – |
-22,000
| Closed | -$179K | – |
|
152
Ocular Therapeutix
OCUL
$1.43B
| – | – |
-18,000
| Closed | -$152K | – |
|
153
Omeros
OMER
$1.19B
| – | – |
-23,000
| Closed | -$243K | – |
|
154
Oscar Health
OSCR
$10.3B
| – | – |
-11,000
| Closed | -$126K | – |
|
155
Vaxcyte
PCVX
$9.8B
| – | – |
-1,261,000
| Closed | -$73.3M | – |
|
156
Precigen
PGEN
$2.27B
| – | – |
-50,000
| Closed | -$194K | – |
|
157
Progyny
PGNY
$2.22B
| – | – |
-18,000
| Closed | -$306K | – |
|
158
Piper Sandler
PIPR
$4.6B
| – | – |
-66,000
| Closed | -$5.05M | – |
|
159
PUT
Invesco Aerospace & Defense ETF
PPA
$7.29B
| – | – |
-3,600,000
| Closed | -$691M | – |
|
160
uniQure
QURE
$1.59B
| – | – |
-14,000
| Closed | -$229K | – |
|
161
Rollins
ROL
$16.8B
| – | – |
-93,000
| Closed | -$4.97M | – |
|
162
Royalty Pharma
RPRX
$28B
| – | – |
-493,000
| Closed | -$23.6M | – |
|
163
Sabra Healthcare REIT
SBRA
$4.93B
| – | – |
-14,000
| Closed | -$269K | – |
|
|
164
Charles Schwab
SCHW
$160B
| – | – |
-3,955,657
| Closed | -$372M | – |
|
165
Schrodinger
SDGR
$1.67B
| – | – |
-17,000
| Closed | -$193K | – |
|
166
SELLAS Life Sciences
SLS
$2.31B
| – | – |
-40,000
| Closed | -$169K | – |
|
167
Syndax Pharmaceuticals
SNDX
$1.2B
| – | – |
-10,000
| Closed | -$234K | – |
|
168
S&P Global
SPGI
$134B
| – | – |
-12,000
| Closed | -$5.1M | – |
|
169
Scholar Rock
SRRK
$5.09B
| – | – |
-7,000
| Closed | -$344K | – |
|
170
Stoke Therapeutics
STOK
$1.69B
| – | – |
-9,000
| Closed | -$293K | – |
|
171
Supernus Pharmaceuticals
SUPN
$2.39B
| – | – |
-4,000
| Closed | -$207K | – |
|
172
Tenable Holdings
TENB
$4.57B
| – | – |
-265,000
| Closed | -$4.48M | – |
|
173
DELISTED
Terns Pharmaceuticals
TERN
| – | – |
-7,000
| Closed | -$369K | – |
|
174
Tenet Healthcare
THC
$21.4B
| – | – |
-452,153
| Closed | -$85.3M | – |
|
175
Timken Company
TKR
$7.58B
| – | – |
-51,000
| Closed | -$5.13M | – |
|
Similar funds
Thomas Steyer's Q2 2026 Portfolio in Review
As of Q2 2026, Thomas Steyer held 194 positions worth $21.7B, up 14% from $19.1B the previous quarter. Its ten largest holdings account for 62% of the portfolio.
Thomas Steyer withdrew a net $3.46B in Q2 2026, closing 105 positions and reducing 23 holdings. Its most notable exit was Charles Schwab, an estimated $372M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 55% of assets, up from 47% a quarter earlier, followed by Miscellaneous and Communication Services.
Against the trend, Thomas Steyer opened a new position in Parabilis Medicines Inc worth $64.8M.
- Thomas Steyer's largest Q2 2026 buy was Parabilis Medicines Inc: 2,368,200 shares worth $64.8M.
- Thomas Steyer added most to Boston Scientific in Q2 2026, an estimated $166M increase.
- Thomas Steyer's biggest Q2 2026 reduction was Microsoft, cutting an estimated $498M.
- Thomas Steyer fully exited Charles Schwab in Q2 2026, selling an estimated $372M.
- Thomas Steyer's ten largest holdings make up 62% of its $21.7B portfolio in Q2 2026.
- Thomas Steyer opened 19 new positions and closed 105 in Q2 2026.
- Thomas Steyer's portfolio value rose 14% quarter-over-quarter to $21.7B.
Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.